Pages that link to "Q35879365"
Jump to navigation
Jump to search
The following pages link to Chemotherapy targeted to cancers through tumoral hormone receptors (Q35879365):
Displaying 50 items.
- International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states (Q24643524) (← links)
- Medical treatment for gastro-entero-pancreatic neuroendocrine tumours (Q26751659) (← links)
- Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors (Q28292264) (← links)
- The novel fusion proteins, GnRH-p53 and GnRHIII-p53, expression and their anti-tumor effect (Q28534798) (← links)
- The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors (Q30486707) (← links)
- Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. (Q33753449) (← links)
- Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. (Q34101055) (← links)
- AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. (Q34274245) (← links)
- Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer (Q34441515) (← links)
- Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231 (Q34486740) (← links)
- Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status (Q34684387) (← links)
- Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. (Q34772221) (← links)
- Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125 (Q34894406) (← links)
- Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide. (Q35162175) (← links)
- Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors (Q35340967) (← links)
- Targeted drug delivery in cancer therapy (Q36200150) (← links)
- Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers (Q36202016) (← links)
- Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108] (Q36236479) (← links)
- Cancer treatment using peptides: current therapies and future prospects (Q36515785) (← links)
- Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs (Q36597647) (← links)
- Issues related to targeted delivery of proteins and peptides (Q36616311) (← links)
- New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones (Q36748502) (← links)
- Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. (Q36861713) (← links)
- Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones (Q36912988) (← links)
- An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK. (Q37012088) (← links)
- Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice (Q37034254) (← links)
- Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108. (Q37093547) (← links)
- Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells (Q37178660) (← links)
- Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. (Q37323454) (← links)
- Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma (Q37381602) (← links)
- Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists (Q37495105) (← links)
- Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives (Q37564373) (← links)
- Receptor-mediated tumor targeting based on peptide hormones (Q37641368) (← links)
- Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors (Q37724516) (← links)
- Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer (Q37859389) (← links)
- Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). (Q38007373) (← links)
- Gonadotropin-releasing hormone targeting for gonadotroph ablation: an approach to non-surgical sterilization (Q38029046) (← links)
- Agonists of luteinizing hormone-releasing hormone in prostate cancer (Q38132229) (← links)
- Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives (Q38216009) (← links)
- The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers (Q38472348) (← links)
- Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells (Q38756598) (← links)
- Oligonucleotide-based theranostic nanoparticles in cancer therapy (Q38814327) (← links)
- Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells (Q38855783) (← links)
- Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety (Q38865705) (← links)
- Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting (Q38882916) (← links)
- Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). (Q38949880) (← links)
- LHRH-Targeted Drug Delivery Systems for Cancer Therapy. (Q38980206) (← links)
- Discovery of LHRH and development of LHRH analogs for prostate cancer treatment (Q39267156) (← links)
- In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites (Q39643108) (← links)
- Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. (Q39739294) (← links)